secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K/A
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001683168-25-001712
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports FY2024 net loss of ~$4.0M, cash $6.2M, advances DNase program
--------------------------------------------------------------------------------

- Net loss for FY2024 ~$4.0M; R&D expenses $3.3M (down 5.9% YoY), G&A $3.4M (down 4.1%).
- Royalty payments from Takeda sublicense ~$2.5M, flat YoY; cash balance $6.2M at year-end.
- Entered Clinical Trial Services Agreement with PeriNess for DNase I studies in pancreatic, colorectal, and solid tumors.
- Extended collaborations with University of Virginia and Scripps Research through 2025.
- Progressing DNase I development program toward IND and first-in-human study for pancreatic carcinoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825001712/0001683168-25-001712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316825001712/xenetic_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-001712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer